Acute Promyelocytic Leukemia Clinical Trial
Official title:
Long-term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated With Arsenic Trioxide (ATO) or Standard Chemotherapy
This is a prospective and international observational study run by the GIMEMA. All data will be centrally collected and analyzed at the GIMEMA Data Center in Rome (Italy). Patients reported outcomes will be collected using internationally validated questionnaires.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00520208 -
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
|
Phase 2 | |
| Suspended |
NCT04996030 -
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT02899169 -
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
|
Phase 3 | |
| Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 | |
| Recruiting |
NCT04793919 -
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT02938858 -
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
|
N/A | |
| Recruiting |
NCT02991066 -
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
|
||
| Terminated |
NCT00985530 -
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
|
Phase 1 | |
| Withdrawn |
NCT00670150 -
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT01064570 -
AIDA 2000 Guidelines
|
Phase 2 | |
| Completed |
NCT01472107 -
Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
|
||
| Completed |
NCT00465933 -
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
|
Phase 4 | |
| Active, not recruiting |
NCT02688140 -
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
|
Phase 3 | |
| Active, not recruiting |
NCT01987297 -
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
|
Phase 4 | |
| Terminated |
NCT00907582 -
ASCT for Relapsed APL After Molecular Remission
|
Phase 2 | |
| Recruiting |
NCT00517712 -
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
|
Phase 2/Phase 3 | |
| Completed |
NCT01902329 -
A Safety Study of SGN-CD33A in AML Patients
|
Phase 1 | |
| Completed |
NCT01404949 -
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
|
Phase 2 | |
| Completed |
NCT00504764 -
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
|
Phase 4 | |
| Completed |
NCT00408278 -
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
|
Phase 4 |